Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Similar Items

• Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
  od: Suzuki, Yasuo, i dr.
  Izdano: (2017)
• Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
  od: Suzuki, Yasuo, i dr.
  Izdano: (2013)
• Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy
  od: Motoya, Satoshi, i dr.
  Izdano: (2018)
• Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis
  od: Suzuki, Yasuo, i dr.
  Izdano: (2019)
• Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3
  od: Colombel, Jean-Frederic, i dr.
  Izdano: (2014)